Details for New Drug Application (NDA): 216857
✉ Email this page to a colleague
The generic ingredient in ENTECAVIR is entecavir. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the entecavir profile page.
Pharmacology for NDA: 216857
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 216857
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ENTECAVIR | entecavir | TABLET;ORAL | 216857 | ANDA | Cameron Pharmaceuticals | 42494-457 | 42494-457-30 | 30 TABLET in 1 BOTTLE (42494-457-30) |
| ENTECAVIR | entecavir | TABLET;ORAL | 216857 | ANDA | Cameron Pharmaceuticals | 42494-458 | 42494-458-30 | 30 TABLET in 1 BOTTLE (42494-458-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.5MG | ||||
| Approval Date: | Dec 23, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Dec 23, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
